Diffuse large B-cell lymphoma trials in Italy
24 of 35 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleAn early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Where
- Bergamo, Bologna, Naples
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Celgene Corp.
See details and how to joinNCT03930953 · EU 2024-515690-10-00 - Phase 3Taking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Ancona, Brescia, Candiolo, Milan, Monza, Novara, Palermo, Ravenna, Rionero In Vulture, Rome
- Age
- 18 years and over
- People
- 1,046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - Phase 2Taking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Brescia, Meldola, Milan, Naples, Rozzano
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - Phase 3Taking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- Meldola, Milan, Modena, Monza, Naples, Novara, Pavia, Perugia, Ravenna, Roma, Turin, Udine, Varese
- Age
- 18 years and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - Phase 1Taking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Bologna, Milan
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - Phase 2/3Taking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Naples, Rozzano
- Age
- 18 years and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - Phase 1Taking peopleIKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- Where
- Candiolo, Milan
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659 - Phase 2Taking peopleA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Where
- Alexandria, Brescia, Meldola, Milan, Naples, Palermo, Reggio Emilia, Rozzano
- Age
- 18 years and over
- People
- 594 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00 - Phase 1Not yet taking people in ItalyStudy to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Where
- Padova, Verona
- Age
- 18 years to 99 years
- People
- 14
- Run by
- Istituto Oncologico Veneto IRCCS
See details and how to joinNCT07906080 · EU 2026-525494-39-00 - Phase 1Taking peopleA Study of ARC-02 in B-cell NHL
- Where
- Aviano, Bergamo, Bologna, Rozzano
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Milan, Rome, Turin
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 1Taking peopleA Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Where
- Bologna, Milan, Rome, Verona
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07195916 · EU 2025-523130-11-00 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Bologna, Milan, Roma, Verona
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - No phaseTaking peopleLifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
- Where
- Ancona, Aviano, Bari, Barletta, Belluno, Bolzano, Brescia, Brindisi, Caltanissetta, Catania, Como, Florence, Lecce, Legnano, Messina, Milan, Modena, Novara, Padova, Pagani, Palermo, Pescara, Piacenza, Pisa, Potenza, Reggio Emilia, Rimini, Roma, Rozzano, Sassari, Sassuolo, Torino, Treviso
- Age
- 18 years to 50 years
- People
- 552
- Run by
- Fondazione Italiana Linfomi - ETS
See details and how to joinNCT05934084 - Phase 1/2Taking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Bologna, Milan, Rome, Rozzano
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - Phase 2Taking peopleCombining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Where
- Bologna, Milan, Naples
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Universität Münster
See details and how to joinNCT07197307 · EU 2023-509861-19-01 - Phase 1Taking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Bologna, Brescia, Milan, Rome
- Age
- 18 years and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - Phase 2Taking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Turin
- Age
- 18 years to 70 years
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - No phaseNot yet taking people in ItalyGeriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
- Where
- Ancona, Avellino, Aviano, Bari, Brescia, Cagliari, Florence, Milan, Monza, Padova, Palermo, Parma, Piacenza, Prato, Ravenna, Reggio Emilia, Roma, Siena, Teramo, Torino, Udine, Verona
- Age
- 70 years and over
- People
- 170
- Run by
- Fondazione Italiana Linfomi - ETS
See details and how to joinNCT07476105 - Phase 1Taking peopleStudy of SGR-1505 in Mature B-Cell Neoplasms
- Where
- Alexandria, Milan, Turin, Verona
- Age
- 18 years and over
- People
- 98 worldwide
- Run by
- Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00 - Phase 2Taking peopleStudy of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
- Where
- Alexandria, Bologna, Cuneo, Milan, Rome, Rozzano
- Age
- 18 years to 99 years
- People
- 50
- Run by
- Istituto Clinico Humanitas
See details and how to joinNCT06918912 · EU 2024-516929-31-00 - Phase 3Taking peopleA Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
- Where
- Aviano, Bari, Milan, Monza, Naples, Orbassano, Reggio Calabria, Rome, Trieste, Udine, Verona
- Age
- 75 years and over
- People
- 300 worldwide
- Run by
- Nordic Lymphoma Group
See details and how to joinNCT04332822 · EU 2022-502887-19-00 - Phase 3Taking peoplePrephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
- Where
- Alexandria, Ancona, Andria, Ascoli Piceno, Avellino, Aviano, Brescia, Cagliari, Chivasso, Florence, Meldola, Milan, Monza, Novara, Palermo, Pavia, Perugia, Pescara, Piacenza, Ponderano, Potenza, Ravenna, Reggio Emilia, Rimini, Rionero In Vulture, Roma, Rome, Salerno, San Giovanni Rotondo, Sassuolo, Siena, Terni, Trieste, Turin, Udine, Venice, Vicenza
- Age
- 65 years and over
- People
- 430
- Run by
- Fondazione Italiana Linfomi - ETS
See details and how to joinNCT04442412 · EU 2024-511637-35-00 - Phase 1/2Taking peopleSafety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Where
- Aviano, Meldola, Milan, Pavia, Verona
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT04502394